A first study in humans was done in patients with metastatic melanoma and sarcoma and showed the ability of this cytokine to increase the number of CD4+ and CD8+ lymphocytes and decrease in the percentage of CD4+ T-regulatory cells suggesting its role in treating lymphopenia. Here, CD8A is linked to lymphopenia.